Beverly Hills, CA4 Active Studies

Diabetic Retinopathy Clinical Trials in Beverly Hills, CA

Find 4 actively recruiting diabetic retinopathy clinical trials in Beverly Hills, CA. Connect with local research sites and explore new treatment options.

4
Active Trials
3
Sponsors
893
Enrolling

Recruiting Diabetic Retinopathy Studies in Beverly Hills

About Diabetic Retinopathy Clinical Trials in Beverly Hills

Diabetic retinopathy is a diabetes complication that affects the blood vessels in the retina and is the leading cause of blindness in working-age adults. Diabetic macular edema (DME) involves fluid accumulation in the macula. Treatment includes anti-VEGF injections, laser therapy, and blood sugar control.

There are currently 4 diabetic retinopathy clinical trials recruiting participants in Beverly Hills, CA. These studies are seeking a combined 893 participants. Research is being sponsored by AbbVie, Boehringer Ingelheim, Genentech, Inc.. Clinical trial participation is free and participants receive study-related medical care at no cost.

Diabetic Retinopathy Clinical Trials in Beverly Hills — FAQ

Are there diabetic retinopathy clinical trials in Beverly Hills?

Yes, there are 4 diabetic retinopathy clinical trials currently recruiting in Beverly Hills, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Beverly Hills?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Beverly Hills research site will contact you about next steps.

Are clinical trials in Beverly Hills free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Beverly Hills studies also compensate for your time and travel.

What diabetic retinopathy treatments are being tested?

The 4 active trials in Beverly Hills are testing new therapies including novel drugs, biologics, and treatment approaches for diabetic retinopathy.

Data updated October 15, 2026 from ClinicalTrials.gov